SynthesisFrontiers in medicine2025
Central nervous system symptoms in mpox patients without HIV co-infection: a meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Co-infection with HIV in patients infected with the mpox virus (MPXV) may pose a potential risk of influencing neurological manifestations. We aimed to synthesize the central nervous system (CNS) symptoms reported by mpox patients without HIV co-infection. Methods: We conducted a search for studies on mpox published in PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang Data, and Weipu Data till 2023/11/19. The type of studies included were cohort studies, case series, case-control trials, and randomized controlled trials. Reviews, editorials, pre-prints, and conference proceedings were excluded. We only included studies that reported neurological manifestations in mpox patients without HIV. STATA (version 16.0) was used to create forest plots that pooled the mean scores of CNS symptoms in mpox patients. Outcomes were presented with 95% confidence interval (95% CI), and heterogeneity was assessed using the Results: We identified 2,311 unique studies, of which 14 (with a total of 989 patients) met the inclusion criteria. The quality of each study was assessed using the Newcastle-Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality (AHRQ) tool. The majority of the included articles were rated as medium quality. The major CNS clinical features were myalgia, headache, and fatigue/asthenia, with pooled mean scores of 0.22 (95% CI: 0.13-0.31), 0.25 (95% CI: 0.17-0.33) and 0.28 (95% CI: 0.21-0.37) in mpox patients without HIV. The results of the sensitivity analysis showed that the meta-analysis results were stable. Additionally, Egger's test ( Conclusion: The MPXV may cause clinical nervous system injuries, including headache, myalgia, and fatigue/asthenia, as observed in approximately 25% (±3%) of the studied population. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024464199, CRD42024464199.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.